[Short-term effects of chemotherapy combined with hydroxycamptothecine and oxaliplatin in treatment of recurrent and metastatic colorectal cancer].
OBJECTIVE
Although 5-fluarouracil (5-FU)-based chemotherapy has become a standard regimen for treatment of recurrent and metastatic colorectal cancer, the efficacy, as a second line therapy, is not high. Thus, it is necessary to find a new regimen as a substitute. This study was to evaluate the short-term effects and toxicity of combination of hydroxycamptothecine (HCPT) plus oxaliplatin (L-OHP) protocol in the treatment of recurrent and metastatic colorectal cancer.


METHODS
47 patients with pathological evidence of recurrent and metastatic colorectal cancer were enrolled and treated with HCPT plus L-OHP regimen for 86 cycles. All patients were treated with (L-OHP 130 mg/m(2), day 1 and HCPT 6 mg/m(2), day 1-4) and the chemotherapy was repeated every 3 weeks. The short-term effects and side effects were evaluated after every 2 cycles for each patient.


RESULTS
38 cases were evaluable and RR [complete remission (CR)+partial remission (PR)] was 36.8% (14/38). KPS was improved in 20 cases (52.6%). In total 86 cycles, leucopenia occurred in 59 cycles (68.6%), 18 cycles (30.5%) in grade III and IV, and diarrhea occurred in 48 cycles (55.8%), 18 cycles (37.5%) in grade III and IV. One year survival rate was 40.0% and medium overall survival (mOS) and medium progression free survival (mPFS) were 11.7 and 7.8 months, respectively.


CONCLUSIONS
HCPT plus L-OHP regimen achieved relatively satisfactory short-term effects in the treatment for colorectal cancer patients, who suffered from recurrence and metastasis after the first-line chemotherapy with 5-FU. The main toxicities of the regimen were leucopenia and diarrhea.
Yao
Yang
Y
Department of Medical Oncology, The Sixth People's Hospital, Shanghai Jiaotong University, Shanghai, 200233, P. R. China. yangyao_6@hotmail.com
Sun
Yuan-Jue
YJ
Zhao
Hui
H
Guo
Yue-Wu
YW
Lin
Feng
F
Cai
Xun
X
Tang
Xiao-Chun
XC
D000230:Adenocarcinoma / Q000188:drug therapy / Q000556:secondary; D000328:Adult; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D003967:Diarrhea / Q000139:chemically induced; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008113:Liver Neoplasms / Q000556:secondary; D008175:Lung Neoplasms / Q000556:secondary; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009364:Neoplasm Recurrence, Local; D009944:Organoplatinum Compounds / Q000008:administration & dosage*; D000077150:Oxaliplatin; D012074:Remission Induction; D015996:Survival Rate
D000972:Antineoplastic Agents, Phytogenic; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; C028098:10-hydroxycamptothecin; D002166:Camptothecin